Filing summary
Source discrepancy: The metadata identifies Lite Strategy, Inc. and 2011 Q1, but the filing text is MEI Pharma, Inc.’s Form 10-Q for the quarter ended September 30, 2012. The summary below reflects the filing text.
Business context and reporting period
MEI Pharma was a development-stage oncology company developing Pracinostat, ME-143 and ME-344. It reported the three months ended September 30, 2012, with comparison to the three months ended September 30, 2011. The company reported no revenue and described ongoing operating losses and negative operating cash flows.
Key financial metrics
| Metric | Three months ended Sep. 30, 2012 | Three months ended Sep. 30, 2011 / comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1.552 million | $1.044 million |
| General and administrative expense | $914,000 | $889,000 |
| Total operating expenses | $2.466 million | $1.933 million |
| Net loss | $2.464 million | $1.612 million |
| Basic and diluted loss per share | $0.12 | $0.17 |
| Net cash used in operating activities | $2.487 million | $1.730 million |
| Cash and cash equivalents at period end | $3.713 million | $4.800 million at Sep. 30, 2011 |
At September 30, 2012, total assets were $4.355 million, including $496,000 of net intangible assets; current liabilities were $1.630 million, and stockholders’ equity was $2.725 million. The filing reports no debt balance. No gross or operating margins are meaningful because the company had no revenue. Cash fell by $2.489 million during the quarter; there was no financing cash inflow in the period.
Material changes versus prior comparable period
- Net loss increased by $852,000, principally as R&D expense rose $508,000. Management attributed the R&D increase mainly to ME-344 Phase I trial and drug-manufacturing costs.
- Operating cash use increased by $757,000. Unlike the prior-year quarter, the current quarter had no financing proceeds.
- Loss per share narrowed from $0.17 to $0.12, while weighted-average shares increased from about 9.59 million to 21.00 million.
- The company acquired Pracinostat-related assets from S*BIO for $500,000 in common stock, recorded as an intangible asset, and entered a Captisol license and supply arrangement with CyDex.
Outlook, risks and unusual items
- Management estimated that the $3.7 million cash balance would fund operations only until early calendar 2013, excluding anticipated proceeds from a proposed financing. The filing states that recurring losses and dependence on additional funding raise substantial doubt about the company’s ability to continue as a going concern if that financing is not completed.
- A November 2012 PIPE was approved, subject to conditions and expected to close in December 2012: 55 million units for $27.5 million, each comprising one common share and a warrant for 0.70 shares at $0.52. The warrants cover up to 38.5 million additional shares, implying substantial potential dilution. The company warned that failure to complete the financing could require it to reduce or cease operations.
- The S*BIO agreement includes potential clinical, regulatory and sales milestone payments of up to $75.2 million, plus sales-based earn-outs. CyDex terms include a non-refundable fee, future milestones and royalties; the filing does not state clear payment amounts.
- MEI expected to initiate a randomized Phase II Pracinostat trial in MDS by the second quarter of calendar 2013. ME-344 Phase I was ongoing; ME-143 Phase I results had been presented in June 2012. These are plans and development updates, not assured outcomes.
- Nasdaq granted continued listing through February 11, 2013, conditional on meeting the $1.00 minimum bid-price requirement for ten consecutive trading days and satisfying other listing requirements. The company planned a one-for-ten reverse stock split.
- Novogen, then the 60% shareholder, planned a distribution of its MEI shares to its own shareholders, subject to approval. The filing also describes the company’s clinical, regulatory, financing, intellectual-property and commercialization risks.
Important facts for investors to verify
- Confirm the issuer and reporting period: the provided filing text conflicts with the request metadata.
- Check whether the $27.5 million PIPE closed, its final terms, and the resulting share and warrant dilution.
- Verify cash runway, subsequent cash use and whether additional financing became necessary.
- Track Nasdaq listing compliance and the timing and effect of any reverse split.
- Review clinical-trial progress, milestone obligations under the S*BIO agreement, and the financial terms of the CyDex agreements.